Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13245MR)

This product GTTS-WQ13245MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ13245MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15391MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TRU-016
GTTS-WQ9629MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ15940MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ7934MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ13584MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA QAX-576
GTTS-WQ14071MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-3918
GTTS-WQ11042MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCLA-128
GTTS-WQ6954MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ESBA-1008
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW